Advance in anticancer drug development
9
1
Issued Date
2018
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
Faculty of Pharmacy Mahidol University
Graduate School of Pharmaceutical Sciences Chiba University
Graduate School of Pharmaceutical Sciences Chiba University
Suggested Citation
Pakatip Ruenraroengsak (2018). Advance in anticancer drug development. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/25188
Title
Advance in anticancer drug development
Author(s)
Other Contributor(s)
Abstract
Cancer is one of the leading cause of death worldwide and responsible for 8.8 million deaths
in 2015. It isrecommended that cancer mortality can be decreased by early detection and
treatment. The new concept of theranostic (or theragnostic) involves simultaneously
diagnostic and targeted therapeutic aiming to reduce delays in cancer treatment which appear
to be crucial for personalized cancer treatment. The treatment can also be performed
immediately after the diagnostic and vice versa to monitor the early response to the given
treatment. Nanotechnology have been explored as a captivated tool for cancer theranosis due
to the passive targeting delivery through extravasation of nanoparticles, 20-200nm in
diameter, at the tumour site via enhanced permeability and retention effect, EPR. In this
review, the recent developed platforms for both cancer nanotheranostics and cancer
nanomedicines are updated. Both the physicochemical properties (particularly size, shape and
surface chemistry) of nanoparticles and the complexity of tumour microenvironment are
extremely important for design anti-cancer drug delivery systems. The golden rule is that the
nanoparticles must reach and achieve their optimum concentrations at the tumour site without
creating any fatal side effect. Several multifunctional nanoparticles were designed and
investigated in vitro and in vivo for their potential uses as anti-cancer drug delivery systems
as well as cancer theranostics. The designs of nanoparticles including liposomes, solid lipid
nanoparticles, dendrimers, biodegradable polymeric-based nanoparticles, carbon nanotubes,
silica nanoparticles and metallic-based nanoparticles will be reviewed and compared.
Description
The 3rd Chiba University-Mahidol University Joint Symposium
on Pharmaceutical Sciences. Hosted by Faculty of Pharmacy, Mahidol University
Thursday August 2, 2018